ストックスクリーナーアプリを入手
1.20
0.83%
-0.01
プレマーケット:
1.20
前日終値:
$1.21
開ける：
$1.22
24時間の取引高:
2.33M
Relative Volume:
4.71
時価総額：
$54.85M
収益：
-
当期純損益:
$-40.56M
株価収益率:
-1.0256
EPS:
-1.17
ネットキャッシュフロー:
$-35.28M
1週間 パフォーマンス:
-7.69%
1か月 パフォーマンス:
-25.93%
6か月 パフォーマンス:
-17.24%
1年 パフォーマンス:
-70.07%
1日の値動き範囲:
$1.02
$1.2795
1週間の範囲:
$1.02
$1.30
52週間の値動き範囲:
$0.8505
$4.32
Pds Biotechnology Corporation Stock (PDSB) Company Profile
名前
Pds Biotechnology Corporation
セクター
電話
800-208-3343
住所
303A COLLEGE ROAD EAST, PRINCETON
PDSB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.20 | 59.42M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-01 | 開始されました | B. Riley Securities | Buy |
| 2021-06-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-09 | 開始されました | Noble Capital Markets | Outperform |
| 2019-10-24 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Pds Biotechnology Corporation (PDSB) 最新ニュース
PDS Biotechnology Corporation Stock Analysis and ForecastMarket-crushing profits - Jammu Links News
What drives PDS Biotechnology Corporation stock priceFree Stock Market Knowledge Sharing - Jammu Links News
Why PDS Biotechnology Corporation stock attracts strong analyst attentionFree Stock Market Knowledge Sharing - Newser
What makes PDS Biotechnology Corporation stock price move sharplyFree Day Trading Recommendations - Newser
How PDS Biotechnology Corporation stock performs during market volatilityLow Risk Consistent Winners - Newser
PDS Biotechnology stock advances as Phase 2 trial meets expansion criteria - Investing.com
PDS Biotechnology completes recruitment for stage one of colorectal cancer trial - Yahoo Finance
PDS Biotechnology Corporation Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - MarketScreener
PDS Biotechnology stock rises after trial meets criteria for expansion By Investing.com - Investing.com Nigeria
PDS Biotechnology stock rises after trial meets criteria for expansion - Investing.com Australia
PDS Biotech's PDS01ADC: A Breakthrough in Cytokine Therapy for Metastatic Colorectal Cancer - AInvest
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results - The Manila Times
PDS Biotech Achieves Crucial Phase 2 Milestone: Colorectal Cancer Drug Shows Promising Early Results - Stock Titan
PDS Biotechnology (PDSB) Retains "Buy" Rating with Price Target Unchanged | PDSB Stock News - GuruFocus
PDSB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Transcript : PDS Biotechnology CorporationSpecial Call - MarketScreener
PDS Biotechnology holds a conference call - TipRanks
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen - Defense World
HC Wainwright Issues Pessimistic Estimate for PDSB Earnings - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright - Defense World
PDS Biotech expands equity incentive plan By Investing.com - Investing.com Canada
PDS Biotech expands equity incentive plan - Investing.com
PDS Biotechnology Approves Equity Plan Amendment at Meeting - TipRanks
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock - Investing.com
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock By Investing.com - Investing.com UK
PDSB Biotechnology's Virtual Event to Discuss Advances in HPV16-Positive HNSCC | PDSB Stock News - GuruFocus
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC - The Manila Times
PDS Biotechnology Corporation to Host Webinar on HPV16-Positive HNSCC and Merck KN-689 Study - Nasdaq
Jane Street Group LLC Invests $58,000 in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Northern Trust Corp Trims Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial By Investing.com - Investing.com South Africa
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - inkl
Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus - TradingView
PDSB: PDS Biotechnology Releases Promising Results from Versamune HPV Studies | PDSB Stock News - GuruFocus
PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - TipRanks
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial - Investing.com India
Clinical Trial Breakthrough: PDS Biotech Achieves 30-Month Survival in Advanced Head and Neck Cancer Patients - Stock Titan
PDS Biotechnology files to sell 9.82M shares of common stock for holders - MSN
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Sh - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDS - GuruFocus
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Shares - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDSB Stock News - GuruFocus
Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to “Hold” - Defense World
PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial - Insider Monkey
Q2 EPS Estimates for PDS Biotechnology Raised by B. Riley - Defense World
PDS Biotech reports extended survival in HPV cancer study - Investing.com Australia
PDS Biotech reports extended survival in HPV cancer study By Investing.com - Investing.com India
Pds Biotechnology Corporation (PDSB) 財務データ
収益
当期純利益
現金流量
EPS
Pds Biotechnology Corporation (PDSB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):